397 related articles for article (PubMed ID: 26212701)
1. Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.
Anghileri E; Castiglione M; Nunziata R; Boffano C; Nazzi V; Acerbi F; Finocchiaro G; Eoli M
Neurosurg Rev; 2016 Jan; 39(1):37-45; discussion 45-6. PubMed ID: 26212701
[TBL] [Abstract][Full Text] [Related]
2. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
4. An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system.
Pietschmann S; von Bueren AO; Kerber MJ; Baumert BG; Kortmann RD; Müller K
PLoS One; 2015; 10(4):e0121592. PubMed ID: 25860797
[TBL] [Abstract][Full Text] [Related]
5. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
Pelloski CE; Mahajan A; Maor M; Chang EL; Woo S; Gilbert M; Colman H; Yang H; Ledoux A; Blair H; Passe S; Jenkins RB; Aldape KD
Clin Cancer Res; 2005 May; 11(9):3326-34. PubMed ID: 15867231
[TBL] [Abstract][Full Text] [Related]
6. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
7. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
Tanwar MK; Gilbert MR; Holland EC
Cancer Res; 2002 Aug; 62(15):4364-8. PubMed ID: 12154041
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
[TBL] [Abstract][Full Text] [Related]
9. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells.
Junker N; Johansen JS; Hansen LT; Lund EL; Kristjansen PE
Cancer Sci; 2005 Mar; 96(3):183-90. PubMed ID: 15771622
[TBL] [Abstract][Full Text] [Related]
10. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
Horbinski C; Wang G; Wiley CA
Int J Clin Exp Pathol; 2010 Jan; 3(3):226-37. PubMed ID: 20224722
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
12. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.
Ma X; Yoshimoto K; Guan Y; Hata N; Mizoguchi M; Sagata N; Murata H; Kuga D; Amano T; Nakamizo A; Sasaki T
Neuro Oncol; 2012 Sep; 14(9):1153-62. PubMed ID: 22844109
[TBL] [Abstract][Full Text] [Related]
13. High CHI3L1 expression is associated with glioma patient survival.
Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
[TBL] [Abstract][Full Text] [Related]
14. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Hegi ME; Janzer RC; Lambiv WL; Gorlia T; Kouwenhoven MC; Hartmann C; von Deimling A; Martinet D; Besuchet Schmutz N; Diserens AC; Hamou MF; Bady P; Weller M; van den Bent MJ; Mason WP; Mirimanoff RO; Stupp R; Mokhtari K; Wesseling P; ;
Acta Neuropathol; 2012 Jun; 123(6):841-52. PubMed ID: 22249618
[TBL] [Abstract][Full Text] [Related]
15. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
[TBL] [Abstract][Full Text] [Related]
16. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
17. Serum YKL-40 following resection for cerebral glioblastoma.
Bernardi D; Padoan A; Ballin A; Sartori M; Manara R; Scienza R; Plebani M; Della Puppa A
J Neurooncol; 2012 Apr; 107(2):299-305. PubMed ID: 22102082
[TBL] [Abstract][Full Text] [Related]
18. Protein and mRNA levels of YKL-40 in high-grade glioma.
Kazakova MH; Staneva DN; Koev IG; Staikov DG; Mateva N; Timonov PT; Miloshev GA; Sarafian VS
Folia Biol (Praha); 2014; 60(6):261-7. PubMed ID: 25629266
[TBL] [Abstract][Full Text] [Related]
19. Multifocal glioblastoma multiforme in the posterior fossa mimicking cerebral metastases: case presentation and review of the current literature.
Walter J; Koch A; Herbold C; Schiffler S; Reichart R; Waschke A; Kalff R
J Neurol Surg A Cent Eur Neurosurg; 2013 Dec; 74 Suppl 1():e30-5. PubMed ID: 23427036
[TBL] [Abstract][Full Text] [Related]
20. Extensive Therapies for Extraneural Metastases from Glioblastoma, as Confirmed with the OncoScan Assay.
Xu M; Wang Y; Xu J; Yao Y; Yu WX; Zhong P
World Neurosurg; 2016 Jun; 90():698.e7-698.e11. PubMed ID: 26852708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
